There is newly released research published in the journal Environmental Health Perspectives regarding BPA interaction with chemotherapy. Their conclusion?
BPA at environmentally relevant doses reduces the efficacy of chemotherapeutic agents. These data provide considerable support to the accumulating evidence that BPA is hazardous to human health.
In other words without using excessive doses of BPA protects both estrogen receptor positive and negative breast cancer tumors. The chemo drugs that were tested are doxorubicin, cisplatin and vinblastine.
Doxorubicin (Adriamycin/Rubex) is also used to treat bladder, head and neck, liver, lung, pancreatic and ovarian cancers as well as some leukemias and lymphomas.
Cisplatin (Platinol) is also used to treat testicular, ovarian and bladder cancers as well as Hodgkins and non Hodgkins lymphomas.
Vinblastine (Alkaban/Velban) is also used to treat lung, bladder, head and neck and other cancers as well as some Hodgkins and non Hodgkins lymphomas.
The research did not report on the effect of BPA on these chemotherapeutic agents with other cancer types. In August 2008 the FDA released the following statement: FDA concludes that an adequate margin of safety exists for BPA at current levels of exposure from food contact uses, for infants and adults.
Here is the link to the entire study in PDF format.